Evidence map›Paper›PMID 39639463›Full record

ArticleHuman vaccines & immunotherapeutics2024

Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis.

Jinqiao Li, Xiaoxia Li, Yueyue Fu, Hongbin Meng, Dan Xu, Wenyi Hou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jinqiao LiDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Xiaoxia LiDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Yueyue FuDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Hongbin MengDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Dan XuDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Wenyi HouDepartment of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignant, clonal proliferative disease of plasma cells that remains incurable. This paper aims to analyze the current research status and emerging trends in immunotherapy for MM through bibliometric methods, thereby providing valuable references and guidance for future research and clinical practice. This study presents a bibliometric analysis of 1,018 English-language publications related to MM immunotherapy, which were published in the Web of Science (WoS) Core Collection database from 2013 to 2023. VOSviewer and CiteSpace were employed to visualize the research hotspots and trends within the field of MM immunotherapy. The United States had the highest number of publications (

Indexed as

BibliometricsImmunotherapyMultiple MyelomaAntibodies, MonoclonalChinaHumansAntibodies, Monoclonaldaratumumabbibliometric analysisbispecific antibodiesCAR-TdaratumumabimmunotherapyMultiple myeloma

Identifiers

PMID39639463
PMCPMC11633138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.